Positive News SentimentPositive NewsNASDAQ:TCRX TScan Therapeutics (TCRX) Stock Price, News & Analysis $5.26 -0.25 (-4.54%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About TScan Therapeutics Stock (NASDAQ:TCRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TScan Therapeutics alerts:Sign Up Key Stats Today's Range$5.21▼$5.5450-Day Range$4.97▼$6.0052-Week Range$2.86▼$9.69Volume169,314 shsAverage Volume246,251 shsMarket Capitalization$278.62 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingBuy Company OverviewTScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More… A Totally New ‘Income Coin’ (Ad)Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, it's such a radical departure from what most people think of when it comes to typical income strategies, I'm calling it: The Perfect Income AltcoinClick here to get access to my 'Perfect Income Altcoin' for just $3 today. TScan Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks61st Percentile Overall ScoreTCRX MarketRank™: TScan Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 479th out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTScan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTScan Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about TScan Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for TScan Therapeutics are expected to decrease in the coming year, from ($1.17) to ($1.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TScan Therapeutics is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TScan Therapeutics is -5.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTScan Therapeutics has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about TScan Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.97% of the float of TScan Therapeutics has been sold short.Short Interest Ratio / Days to CoverTScan Therapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in TScan Therapeutics has recently increased by 15.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTScan Therapeutics does not currently pay a dividend.Dividend GrowthTScan Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.97% of the float of TScan Therapeutics has been sold short.Short Interest Ratio / Days to CoverTScan Therapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in TScan Therapeutics has recently increased by 15.00%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News SentimentN/A News SentimentTScan Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.Search Interest1 people have searched for TCRX on MarketBeat in the last 30 days. MarketBeat Follows3 people have added TScan Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, TScan Therapeutics insiders have sold 1,053.10% more of their company's stock than they have bought. Specifically, they have bought $82,550.00 in company stock and sold $951,885.00 in company stock.Percentage Held by InsidersOnly 2.76% of the stock of TScan Therapeutics is held by insiders.Percentage Held by Institutions82.83% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TScan Therapeutics' insider trading history. Receive TCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRX Stock News HeadlinesBarbara Klencke Acquires 5,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) StockSeptember 25, 2024 | insidertrades.comTScan Therapeutics (NASDAQ:TCRX) and Sorrento Therapeutics (OTCMKTS:SRNEQ) Head-To-Head ReviewOctober 7, 2024 | americanbankingnews.comA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, it's such a radical departure from what most people think of when it comes to typical income strategies, I'm calling it: The Perfect Income AltcoinOctober 17, 2024 | Crypto 101 Media (Ad)TScan Therapeutics (NASDAQ:TCRX) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comTScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual MeetingOctober 4, 2024 | globenewswire.comDirector of TScan Therapeutics Barbara Klencke Buys 18% More SharesAugust 29, 2024 | finance.yahoo.comTScan Therapeutics to Participate in Upcoming Investor ConferencesAugust 29, 2024 | globenewswire.comTScan Therapeutics (TCRX) Gets a Buy from Morgan StanleyAugust 28, 2024 | markets.businessinsider.comSee More Headlines TCRX Stock Analysis - Frequently Asked Questions How have TCRX shares performed this year? TScan Therapeutics' stock was trading at $5.83 on January 1st, 2024. Since then, TCRX shares have decreased by 9.8% and is now trading at $5.26. View the best growth stocks for 2024 here. How were TScan Therapeutics' earnings last quarter? TScan Therapeutics, Inc. (NASDAQ:TCRX) posted its quarterly earnings results on Monday, August, 12th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.02. The business had revenue of $0.54 million for the quarter, compared to analysts' expectations of $1.55 million. TScan Therapeutics had a negative trailing twelve-month return on equity of 59.83% and a negative net margin of 855.84%. When did TScan Therapeutics IPO? TScan Therapeutics (TCRX) raised $100 million in an initial public offering on Friday, July 16th 2021. The company issued 6,250,000 shares at $15.00-$17.00 per share. Who are TScan Therapeutics' major shareholders? Top institutional shareholders of TScan Therapeutics include SG Americas Securities LLC (0.03%). Insiders that own company stock include Lynx1 Capital Management Lp, David P Southwell, Timothy J Barberich, Barbara Klencke, Brian M Silver and Zoran Zdraveski. View institutional ownership trends. How do I buy shares of TScan Therapeutics? Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of TScan Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that TScan Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings8/12/2024Today10/17/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TCRX CUSIPN/A CIK1783328 Webwww.tscan.com Phone857-399-9500FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$15.00 Low Stock Price Target$10.00 Potential Upside/Downside+128.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,220,000.00 Net Margins-855.84% Pretax Margin-855.84% Return on Equity-59.83% Return on Assets-35.42% Debt Debt-to-Equity Ratio0.08 Current Ratio7.77 Quick Ratio7.77 Sales & Book Value Annual Sales$21.05 million Price / Sales13.24 Cash FlowN/A Price / Cash FlowN/A Book Value$3.15 per share Price / Book1.67Miscellaneous Outstanding Shares52,970,000Free Float51,512,000Market Cap$278.62 million OptionableNot Optionable Beta0.77 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:TCRX) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.